Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
Fate Therapeutics (NASDAQ: FATE) announced a conference call and live audio webcast scheduled for November 3, 2022 at 5:00 PM ET to discuss its third quarter 2022 financial results and provide a corporate update. This event reflects the company's ongoing commitment to transparency with its investors. The call will be accessible via registration, and an archived version will be available on the company's website shortly after the event.
- Scheduled conference call indicates proactive investor communication regarding financial results.
- Focus on third quarter results showcases ongoing corporate updates.
- None.
SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Thursday, November 3, 2022 at 5:00 PM ET to report its third quarter 2022 financial results and provide a corporate update.
In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com
FAQ
What date will Fate Therapeutics report its third quarter 2022 financial results?
Where can I access the live webcast for Fate Therapeutics' conference call?
What is the purpose of the Fate Therapeutics conference call on November 3, 2022?
How can I participate in the Fate Therapeutics conference call?
